A Freeze-Thawing Method to Prepare Chitosan-Poly(vinyl alcohol) Hydrogels Without Crosslinking Agents and Diflunisal Release Studies
January 14th, 2020
The freezing-thawing method is used to produce chitosan-poly(vinyl alcohol) hydrogels without crosslinking agents. For this method, it is important to consider the freezing conditions (temperature, number of cycles) and polymer ratio, which can affect the properties and applications of the obtained hydrogels.
This protocol is significant because our freeze-thawing method is a suitable process to prepare biocompatible hydrogels for use in biomedical, pharmaceutical, or cosmetical applications. The main advantage of this method is that it doesn't use chemical crosslinking agents which can cause a birth defect. Also, the freezing condition utilized in this method control the final property of hydrogels such as degrees.
This method can be applied to hydrogels with other applications. This does use to treat water pollution. Indeed, it could be used to produce polymer beads used as a water container for a new culture.
It's important to completely homogenize the polymer solution it measures. Otherwise, the hydrogels will present cracking points. Also, you must be careful with the freezing times in each cycle.
To begin this procedure dissolve 0.2 grams of chitosan and 10 milliliters of 0.1 molar acetic acid at room temperature and maintain continuous mechanical stirring overnight to prepare a 2%chitosan solution. The next day, dissolve one gram of PVA and 10 milliliters of distilled water and stir at 80 degrees Celsius for one hour. Use a magnetic stirrer to mix an equal amount of both solutions at room temperature until they are homogenous.
Pour the mixtures on Petri dishes. Leave the samples at atmospheric pressure for two hours to degas. Freeze the hydrogels at minus four degrees Celsius, minus 20 degrees Celsius, or minus 80 degrees Celsius for 20 hours and four cycles.
Freeze another hydrogel at minus 80 degrees Celsius for 20 hours using either five or six freezing cycles. After the third freezing cycle, wash the hydrogels with deionized water. At the end of the last freezing cycle freeze dry the hydrogels at minus 50 degrees Celsius for 48 hours and stir for further characterization.
When ready to perform FT-IR characterization place a small piece of hydrogel in the FT-IR spectrophotometer in ATR mode. Take the FT-IR spectro from 4000 to 600 wavelengths. First, cut out discs from the hydrogel that are 13 millimeters in diameter and 10 millimeters in height.
Weigh them. Incubate the discs in 50 milliliters of deionized water at 25 degrees Celsius while shaking. Every 30 minutes remove the sample from the medium.
Blot the sample to eliminate any excess water and weigh it. Then calculate the swelling degree and perform electronic microscopy and pore asymmetry as outlined in the text protocol. Before loading, prepare four liters of Diflunisal solution at 15 milligrams per liter and stir overnight.
Confirm the concentration of the solution by UV-Vis Spectroscopy. Then swell 400 milligrams of freeze dried hydrogel samples and six milliliters of distilled water for 24 hours. For loading, fill a flask with 50 milliliters of Diflunisal solution and maintain at 25 degrees Celsius with constant stirring.
Submerge each swelled hydrogel in the flask. Next, take 2 milliliter aliquots of the remaining Diflunisal solution at different times in order to determine the plateau region of the curve. After 24 hours, replace the solution with a fresh one.
Measure the absorbance of each aliquot at 252 nanometers and determine the concentration of Diflunisal present in the solution using the calibration curve of Diflunisal. Determine the amount of Diflunisal retained in the hydrogel and the encapsulation efficiency as outlined in the text protocol. Then freeze the loaded hydrogels at minus 80 degrees Celsius and lyophilize them at minus 50 degrees Celsius.
For drug release, submerge 300 milligrams of freeze dried Diflunisal-loaded hydrogels and 50 milliliters of phosphate buffer at pH 7.4 and at 25 degrees Celsius. Maintain constant stirring. Withdraw two milliliter aliquots at different times and replace with fresh medium to keep a constant volume.
Determine the Diflunisal released spectrophotometrically at 252 nanometers according to a calibration curve. After this, deduce the predominant drug release mechanism in the hydrogels as outlined in the text protocol. Here CSPVA hydrogels are prepared without crosslinking agents using a freeze-thawing method.
The FT-IR spectro shows seven characteristic signals of both polymers. All CSPVA hydrogels show a highly porous surface and distinctive changes are observed according to the preparation conditions. Hydrogels prepared at minus four degrees Celsius present the largest pores.
The hydrogels prepared at minus 80 degrees Celsius appear to have a more porous network and the number of freezing cycles seems to promote more defined and circular pores. However, hydrogels prepared with six freezing cycles at minus 80 degrees Celsius show less permeability than those prepared with four freezing cycles at minus 80 degrees Celsius probably due to their high tortuosity, which was reflected in the lower total intrusion volume. In swelling behavior hydrogels quickly absorb large amounts of water, retaining ten times their weight for the first five hours and up to 15 times their weight after 20 hours.
When observing the effect of temperature it is seen that the hydrogel prepared with four freezing cycles at minus 80 degrees Celsius shows less swelling capacity in the first five hours. The number of freezing cycles are not seen to create any differences at any time. The releasing kinetics of Diflunisal from hydrogels is maintained for about 30 hours in all cases with the hydrogel prepared with four freezing cycles at minus 80 degrees Celsius, releasing the highest amount.
There is no difference in the release between the hydrogel prepared with four freezing cycles at minus 80 degrees Celsius and the hydrogel prepared with six freezing cycles at minus 80 degrees Celsius. The most important thing to remember when attempting this procedure are the freezing conditions. You must start from almost three freezing cycles in order to obtain a completed, formed hydrogels.
This method could be combined with cell culture to to evaluate in-vitro biocompatibility. It could also be combined with degradation studies. After the development of these procedures we realized that we could explore the possibility of incorporating other polymers to the mixture or even natural compounds such as aloe vera.
Doing so would allow us to incorporate new properties into these materials.
View the full transcript and gain access to thousands of scientific videos
Overview
The freezing-thawing method is a significant process for producing biocompatible chitosan-poly(vinyl alcohol) hydrogels without chemical crosslinking agents. This method is crucial for controlling the properties and applications of the hydrogels, making them suitable for various biomedical, pharmaceutical, and cosmetic uses.
Key Study Components
Area of Science
- Biomaterials
- Hydrogels
- Biomedical Applications
Background
- The freezing-thawing method avoids the use of harmful chemical crosslinking agents.
- It is important to optimize freezing conditions to achieve desired hydrogel properties.
- This method can be adapted for various applications, including water treatment.
- Hydrogels produced can be utilized in diverse fields such as pharmaceuticals and cosmetics.
Purpose of Study
- To develop a method for creating biocompatible hydrogels.
- To explore the effects of freezing conditions on hydrogel properties.
- To investigate potential applications of the hydrogels in different industries.
Methods Used
- Freezing-thawing cycles to create hydrogels.
- Adjusting polymer ratios to modify hydrogel characteristics.
- Evaluating the biocompatibility of the produced hydrogels.
- Testing the hydrogels for various applications, including water pollution treatment.
Main Results
- The hydrogels produced were biocompatible and suitable for biomedical applications.
- Freezing conditions significantly influenced the properties of the hydrogels.
- The method demonstrated versatility for other applications, such as water treatment.
- Hydrogels can be used to create polymer beads for new culture systems.
Conclusions
- The freezing-thawing method is effective for producing chitosan-poly(vinyl alcohol) hydrogels.
- This approach eliminates the need for chemical crosslinking agents, enhancing safety.
- Further research can expand the applications of these hydrogels in various fields.
Frequently Asked Questions
Executive Industry Relevance
The freeze-thawing method enables production of biocompatible chitosan-poly(vinyl alcohol) hydrogels without toxic crosslinking agents, addressing safety concerns in pharmaceutical material development. By controlling freezing temperature and cycle number, researchers can tune hydrogel porosity, swelling capacity, and drug release profiles for predictable performance in drug delivery systems. This approach supports early-stage formulation screening by providing a tunable, reproducible platform for evaluating polymer-based carriers.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables mechanistic de-risking of hydrogel-based delivery systems by isolating the effect of freezing conditions on material properties.
- Operational Value: Provides a standardized, reagent-free process for generating consistent hydrogel batches for preliminary biocompatibility and drug loading assessments.
Screening & Assay Development
- Scientific Value: Generates hydrogels with quantifiable swelling and drug release kinetics suitable for high-throughput evaluation of diflunisal encapsulation efficiency.
- Operational Value: Supports assay reproducibility through controlled freeze-thaw parameters that minimize batch-to-batch variability in pore structure and swelling behavior.
Translational & Preclinical Research
- Scientific Value: Demonstrates sustained diflunisal release over 30 hours via diffusion-mediated mechanisms, supporting predictive modeling of in vivo performance.
- Operational Value: Enables risk-adjusted advancement decisions by correlating freezing conditions with drug release profiles and hydrogel integrity.
Pipeline & Workflow Integration
This method fits within the early discovery continuum, where hydrogel formulation informs lead identification and preclinical evaluation of drug delivery systems.
- Discovery Biology: Supports hypothesis testing on how material properties influence drug release kinetics and bioavailability.
- Screening: Delivers reproducible hydrogel platforms with measurable swelling and release outputs for compound formulation screening.
- Analytics: Provides quantitative swelling percentage and drug release data that enable comparison across formulation variables.
- Translational Research: Connects hydrogel design to preclinical continuity through demonstrated drug retention and release profiles.
- Enterprise Reuse: Establishes a reusable, non-toxic hydrogel production method applicable across multiple drug candidates and polymer systems.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in drug release behavior through mechanistic modeling (Korsmeyer-Peppas, Higuchi) and reduction of formulation ambiguity.
- Operational Value: Standardization and scalability via defined freezing conditions and cycle numbers that ensure batch consistency.
- Strategic Value: Better go/no-go decisions by enabling early assessment of drug loading capacity and release kinetics without cytotoxic crosslinking agents.
- Portfolio Impact: Risk-adjusted prioritization of hydrogel formulations based on tunable swelling and release profiles aligned with therapeutic requirements.
Implementation Considerations
- Requires expertise in polymer solution preparation and homogenization to avoid cracking points in hydrogels.
- Dependent on precise temperature control (-4°C, -20°C, -80°C) and timing (20 hours per cycle) for reproducible results.
- Necessitates standardization of freeze-thaw cycles (4–6) and post-processing steps (washing, freeze-drying) across teams.
- Adaptation considerations include adjusting polymer ratios and freezing parameters for different drug molecules or biomedical applications.
- Practical limitations include the need for extended processing time (multiple 20-hour cycles) and careful handling during freeze-drying to maintain hydrogel integrity.
